Cidara Therapeutics, Inc.
CDTX
$220.98
$1.090.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -525.72% | -418.81% | -153.02% | -242.85% | 19.95% |
| Total Depreciation and Amortization | 4.49% | 67.52% | 19.01% | 49.15% | 44.44% |
| Total Amortization of Deferred Charges | -100.00% | -100.00% | 100.00% | -79.22% | 102.33% |
| Total Other Non-Cash Items | -59.26% | -131.63% | -107.64% | -4.92% | -20.96% |
| Change in Net Operating Assets | 268.50% | -541.36% | -72.35% | 142.27% | -887.40% |
| Cash from Operations | -137.13% | -514.38% | -384.43% | -224.33% | -82.54% |
| Capital Expenditure | 100.00% | 67.58% | 75.58% | 74.46% | 8.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -57,321.82% | 124.16% | 118.20% | 74.46% | 8.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.80% | -302.00% | -302.00% | -- | -- |
| Issuance of Common Stock | 6,024,312.50% | 6,020,600.00% | 1,230,000.00% | 274.48% | -99.97% |
| Repurchase of Common Stock | 100.00% | -174.36% | 64.33% | 44.06% | 44.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 3,525.00% | -- | -- | -- |
| Cash from Financing | 180,559.55% | 566,552.94% | 28,452.60% | 276.89% | -101.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 404.76% | 1,746.48% | 153.38% | 722.05% | -1,184.82% |